Analyst Price Targets — NPCE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 11:04 am | — | H.C. Wainwright | $19.00 | $16.23 | TheFly | NeuroPace price target raised to $19 from $18 at H.C. Wainwright |
| December 16, 2025 12:49 pm | — | UBS | $22.00 | $15.93 | TheFly | NeuroPace price target raised to $22 from $18 at UBS |
| December 9, 2025 12:58 pm | Priya Sachdeva | UBS | $18.00 | $16.37 | StreetInsider | UBS Reiterates Buy Rating on NeuroPace Inc (NPCE) Post NAUTILUS Trial Results |
| November 5, 2025 11:20 am | Mike Kratky | Leerink Partners | $19.00 | $9.40 | StreetInsider | NeuroPace Inc (NPCE) PT Raised to $19 at Leerink Partners |
| November 5, 2025 11:04 am | Ross Osborn | Cantor Fitzgerald | $16.00 | $9.40 | StreetInsider | Cantor Fitzgerald Says NeuroPace Inc (NPCE) Remains a Top Pick |
| August 14, 2024 6:30 am | Vik Chopra | Wells Fargo | $15.00 | $7.28 | TheFly | NeuroPace price target lowered to $15 from $20 at Wells Fargo |
| May 23, 2024 8:44 am | Frank Takkinen | Lake Street | $20.00 | $7.99 | TheFly | NeuroPace post Q1 move 'overdone,' says Lake Street |
| March 14, 2024 5:08 am | Larry Biegelsen | Wells Fargo | $20.00 | $13.63 | StreetInsider | Wells Fargo Upgrades NeuroPace Inc (NPCE) to Overweight |
| November 10, 2023 2:34 pm | Ross Osborn | Cantor Fitzgerald | $11.00 | $7.85 | Benzinga | Epilepsy-Focused MedTech NeuroPace Has Attractive Entry Point, Competitive Position |
| July 15, 2022 11:42 am | — | Morgan Stanley | $5.50 | $5.74 | Benzinga | Morgan Stanley Maintains Underweight on NeuroPace, Lowers Price Target to $5.5 |
Latest News for NPCE
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference. The presentation will be…
Integer (NYSE: ITGR - Get Free Report) and NeuroPace (NASDAQ: NPCE - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends. Insider and Institutional Ownership 99.3% of Integer shares are held
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NPCE.
U.S. House Trading
No House trades found for NPCE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.